Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)

• Drug: Avelumab
  
  Administered by IV once every two weeks in doses of either 5 mg/kg or 10 mg/kg
  Other Name: MSB0010718C
• Drug: PF-06463922
  
  Tablets taken orally once every day in doses of either 100mg, 75mg, or 50mg.
• Drug: Crizotinib
  
  Capsules. Taken orally once or twice every day in doses of either 200mg or 250mg.
  Other Name: PF-02341066

• Experimental: Group A
  
  ALK negative Non-Small Cell Lung Cancer
  Interventions:
  

  • Drug: Avelumab
  • Drug: Crizotinib
• Experimental: Group B
  
  ALK positive Non-Small Cell Lung Cancer
  Interventions:
  

  • Drug: Avelumab
  • Drug: PF-06463922

• Inclusion Criteria
• Diagnosis of advanced or metastatic NSCLC. Group A must be ALK negative NSCLC and Group B must be ALK positive NSCLC
• Group A at least one prior regimen of therapy
• Group B any number of prior regimens.
• Mandatory tumor tissue available
• At least one measurable lesion
• ECOG Performance status 0 or 1
• Adequate bone marrow, renal, liver and pancreatic function
• Negative pregnancy test for females of childbearing potential
• Group B Phase 2: No prior systemic treatment for advanced or metastatic disease (adjuvant and/or neoadjuvant therapies are allowed if completed at least 6 months prior to study entry. No prior tyrosine kinase inhibitor therapy is allowed at any time prior to study entry)

Exclusion Criteria:

• No prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody.
• No Severe or Chronic medical conditions including gastrointestinal abnormalities or significant cardiac history
• No active infection requiring systemic therapy
• Prior organ transplantation including allogenic stem cell transplantation.